EYPT

EyePoint, Inc.
CAPPED RATING

pSivida Corp develops tiny, sustained-release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years.

EyePoint, Inc. (EYPT) is rated D+ (1.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B); its weakest is Revisions (F). The rating has held at D+ for 3 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
1.5 / 5.0
D+
Value
B
Factor Score 3.3 / 5.0
Growth
C+
Factor Score 2.8 / 5.0
Profitability
D-
Factor Score 1.1 / 5.0
Momentum
F
Factor Score 0.4 / 5.0
Revisions
F
Factor Score 0.0 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -0.2
EV / EBITDA 0.4
Rev Growth YoY -90.5%
Gross Margin 0.0%
Price Return 3M -97.0%
Price Return 12M -96.4%
Catalyst Signal 0.00
Market Cap $34.8M
TTM Revenue $2.8M
Price / Sales 12.5
ROE -148.7%

Historical Factor Score Progression

Held D+ for 3 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 B (3.3) C+ (2.8) D- (1.1) F (0.4) F (0.0) D+ (1.5)
2026-11-04 B (3.3) C+ (2.8) D- (1.1) F (0.4) F (0.0) D+ (1.5)
2026-10-28 B (3.3) C+ (2.8) D (1.2) F (0.4) F (0.0) D+ (1.5)
2026-10-21 B (3.3) C+ (2.8) D- (1.1) F (0.5) F (0.0) D+ (1.5)
2026-10-14 C (2.4) D (1.4) D- (1.1) F (0.5) F (0.0) D- (1.1)
Page 1 of 8
…